Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

NET are heterogeneous tumors that arise from the neuroendocrine ... in 1% of CABOMETYX patients. Monitor for signs and symptoms, and discontinue CABOMETYX in patients with Grade 4 fistulas or ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

1 The drug is indicated to treat ... clinical director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute ...

Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...

A clinical trial for patients with high-grade neuroendocrine tumors is ... strengthening the attack against the tumor, said Chauhan. The new phase 1 trial will enroll about 36 people whose tumors ...

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors.